Predictors of inappropriate and excessive use of reliever medications in asthma: a 16-year population-based study

Hamid Tavakoli, J. Mark FitzGeraldLarry D. Lynd and Mohsen Sadatsafavi

Abstract

Background

Understanding factors associated with the inappropriate or excessive use of short-acting beta agonists (SABA) can help develop better policies.

Methods

We used British Columbian (BC)‘s administrative health data (1997–2014) to create a retrospective cohort of asthma patients aged between 14 and 55 years. The primary and secondary outcomes were, respectively, inappropriate and excessive use of SABA based on a previously validated definition. Exposures were categorised into groups comprising socio-demographic variables, indicators of type and quality of asthma care, and burden of comorbid conditions.

Results

343,520 individuals (56.3% female, average age 30.5) satisfied the asthma case definition, contributing 2.6 million person-years. 7.3% of person-years were categorised as inappropriate SABA use and 0.9% as excessive use. Several factors were associated with lower likelihood of inappropriate use, including female sex, higher socio-economic status, higher continuity of care, having received pulmonary function test in the previous year, visited a specialist in the previous year, and the use of inhaled corticosteroids in the previous year. An asthma-related outpatient visit to a general practitioner in the previous year was associated with a higher likelihood of inappropriate SABA use. Similar associations were found for excessive SABA use with the exception that visit to respirologist and the use of systemic corticosteroids were associated with increased likelihood of excessive use.

Conclusions

Despite proven safety issues, inappropriate SABA use is still prevalent. Several factors belonging to patients’ characteristics and type/quality of care were associated with inappropriate use of SABAs and can be used to risk-stratify patients for targeted attempts to reduce this preventable cause of adverse asthma outcomes.

Download PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @worldallergy: The AAAAI/WAO Joint Congress is only 1 week away. Be sure to follow #AAAAIWAO18 to hear about all the latest research in…
2hreplyretweetfavorite
Interasma RT @Aller_MD: Study: Researchers Retrained Immune Systems of Mice to Switch Off Anaphylaxis https://t.co/NEjS1hZxDt https://t.co/GixFWhWvoC
2hreplyretweetfavorite
Interasma RT @Aller_MD: Integration of eHealth Tools in the Process of Workplace Health Promotion: Proposal for Design and Implementation https://t.c…
3hreplyretweetfavorite
Interasma RT @Aller_MD: Aimmune's Peanut Allergy Drug Meets Main Goal, Shares Surge https://t.co/cSVVr9Cm48 https://t.co/OQZVlq8Wfx
3hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: EUFOREA on Twitter: "The EU summit 2018 on #mhealth, air pollution &… https://t.co/yZWlx0YgdD, see more https://t.…
3hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma